+Vote!
Business Wire (Free subscription) | 10 hours ago
Zacks Analyst Blog Highlights:Bristol-Myers Squibb Co.,ImClone Systems Inc., LSI Corp, Infineon Technologies A.G. and ConocoPhillips. CHICAGO--()--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ...
+Vote!
The Boston Business Journal (Free subscription) | 10/02/2008
Bristol-Myers Squibb Co. has named a local Wyeth executive as general manager for its $750 million biomanufacturing facility under construction in Devens. (BMY)
+Vote!
The Washington Times (Free subscription) | 4 hours ago
Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co.
2Vote!
Seattle Times (Free subscription) | 6 hours ago
Eli Lilly & Co. has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand Lilly's cancer treatment pipeline a few years before several patent expirations hit the drug maker.
1Vote!
Seattle Post-Intelligencer (Free subscription) | 8 hours ago
NEW YORK -- The drugmaker Eli Lilly & Co. says it has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand its pipeline of cancer treatments.
- send to a friend
-
Explore : Biotechnologies, Biotechnology, Bristol, Business, Cities and Towns, Drug Manufacturers, Eli Lilly, Imclone Systems, New York, New York City, South West England
+Vote!
Law Blog - WSJ.com (Free subscription) | 9 hours ago
The agreement is a defeat for Bristol-Myers Squibb Co., which last month offered to by the 83% of the company it didn't own for $60 a share. That bid essentially put ImClone up for sale and resulted in Lilly's interest, ...
